Navigation Links
Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting

logenous leukemia or advanced myelodysplastic syndromes. Data from this trial are expected in 2007.

Since their introduction over 40 years ago, anti-mitotic drugs (taxanes and vinca alkaloids) have advanced the treatment of cancer and are commonly used for the treatment of several tumor types. However, these drugs have demonstrated limited treatment benefit against certain cancers. In addition, these drugs target tubulin, a cytoskeletal protein involved not only in mitosis and cell proliferation, but also in other important cellular functions. Inhibition of these other cellular functions produces dose- limiting toxicities such as peripheral neuropathy, an impairment of peripheral nervous system function. Neuropathies are thought to result when these drugs interfere with the dynamics of microtubule filaments that are responsible for the long-distance transport of important cellular components within nerve cells.

Mitotic kinesins are essential to mitosis, and, unlike tubulin, appear to have no role in unrelated cellular functions. Cytokinetics believes that drugs that inhibit KSP and CENP-E and other mitotic kinesins may represent the next generation of anti-mitotic cancer drugs by arresting mitosis and cell proliferation without impacting unrelated, normal cellular functions, thereby avoiding many of the toxicities commonly experienced by patients treated with existing anti-mitotic drugs.

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Cytokinetics' development efforts are directed to advancing multiple drug candidates through clinical trials to demonstrate proof-of-concept in humans, specifically in the areas of heart failure and cancer. Cytokinetics' cardiovascular disease program is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound, CK-182
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Developed by Roche under the trade name ... in the world. In Feb.26, 2010, it was approved ... injections available in China all ...
(Date:8/28/2015)... , Aug. 28, 2015  Today, in final recognition ... Contact Lens Health Week, 1-800 Contacts is sharing how ... that contact lens wearers who do not properly care ... for eye infections. Most contact lens ... but a clean lens case is sometimes overlooked.  When ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on ... their offering. Developed by Novo Nordisk, ... is an important drug for the treatment of ... a fast- acting insulin analog, starts working fast ...
Breaking Medicine Technology:Investigation Report on China's Bevacizumab Market 2015-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... S.C., April 12, 2011 Southern Home Medical ... healthcare services, healthcare professionals and equipment to medical ... results from operations for fiscal year 2010 have ... from Encore Medical Staffing. In a ...
... ST. PAUL, Minn., April 12, 2011 According to ... safety edit, designed to require provider prior authorization (PA) ... use of insulin or nitrate (CIN), potentially decreased members, ... at the Academy of Managed Care Pharmacy,s 23rd Annual ...
Cached Medicine Technology:Southern Home Medical Equipment Reports Additional Revenues and Profits for 2010 2Point-of-Sale Electronic Safety Check May Reduce Heart Attack Risk for Diabetic Patients 2
(Date:8/30/2015)... , ... August 30, 2015 , ... ... (HIFU) medical devices for the treatment of prostate cancer, has announced the roll-out ... summer at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane ... Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” ... through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E ...
(Date:8/29/2015)... Irvine, CA (PRWEB) , ... August 29, 2015 , ... ... on a mission. His mission is to increase acceptance of the chiropractic field ... pain medications that further debilitate them. Although Chiropractic was made available to the ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... obstructive pulmonary disease (including emphysema), or asthma, are at higher risk from wildfire ... heart attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are also ...
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College joined nine ... experience as part of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models ... the third Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... , , TAMPA, Fla., July 23 ... scrubs and chemical drugs and armed himself with a movie ... due to preventable illness, Burton found an alarming connection between ... of death. Now he,s going to tell the world what ...
... recent years. This is fact, but what is not clear ... have shown that family conflict is not a significant factor. ... striking: in Spain, 24% of women take antidepressants and more ... is often related to family or work-related problems. We wanted ...
... Ind., July 23 Hill-Rom Holdings, Inc.,s, (NYSE: HRC ) ... 2009. You are invited to participate in a webcast the following ... Earnings Release: Hill-Rom Holdings, Inc.,s Fiscal 2009 Third Quarter ... the public after the NYSE close on Thursday, August 6, 2009. ...
... YORK, July 23 The U.S. Fund for UNICEF announced today ... UNICEF,s mission to save, protect and improve the lives of children ... reducing the number of preventable deaths of children, from 25,000 per ... will lead the steering committee and host UNICEF,s Next Generation launch ...
... July 23 At the 2009 American Association of ... Anaheim, California, Elekta will demonstrate how the company,s comprehensive ... cancer care with precision and ease. , , ... deliver radiation treatments, Elekta booth 423 will highlight treatment ...
... , WARREN, N.J., July 23 MonoSol Rx, the ... dissolving thin film pharmaceutical products, today announced the appointment of Theodore ... will report to Keith J. Kendall, Executive Vice President and CFO. ... are pleased to welcome Ted to MonoSol Rx and look forward ...
Cached Medicine News:Health News:Nurse Turned Filmmaker Makes Lifesaving Film 2Health News:Almost 1 quarter of Spanish women take antidepressants 2Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Third Quarter Earnings Webcast 2Health News:U.S. Fund for UNICEF and Jenna Bush Hager Announce Next Generation Initiative to Improve Lives of Children Around the World 2Health News:Comprehensive VMAT Solution From Elekta on Center Stage at 2009 AAPM Annual Meeting 2Health News:Comprehensive VMAT Solution From Elekta on Center Stage at 2009 AAPM Annual Meeting 3Health News:MonoSol Rx Appoints Theodore Clemente Vice President Business Development 2Health News:MonoSol Rx Appoints Theodore Clemente Vice President Business Development 3
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
Medicine Products: